Exploring radiomics as a predictor of hypertrophy of future liver remnant after portal vein embolization in biliary malignancies: a retrospective cohort study.

Objective: Portal vein embolization (PVE) is an established procedure to induce hypertrophy of the future liver remnant (FLR) in cases requiring major hepatectomies. However, prediction of FLR hypertrophy prior to PVE is challenging. The study aims to evaluate the utility of CT derived radiomics of the liver and clinical and laboratory parameters in predicting the hypertrophy of FLR.

Novel framework for response evaluation criteria in grade 1/2 neuroendocrine tumors (RECIN) following [Lu]Lu-DOTATATE therapy: post-hoc analysis of the phase 2 LuCAP trial.

Purpose: Treatment response assessment in grade 1/2 neuroendocrine tumors (NETs) has been a key challenge due to their indolent nature. Here, we propose the novel response evaluation criteria with [Ga]Ga-somatostatin analogue (SSA)-PET/CT in grade 1/2 NETs (RECIN) following [Lu]Lu-DOTATATE therapy and evaluate its survival impact vis-à-vis conventional radiographic response assessment.

Methods: This was a post-hoc analysis of the phase 2 LuCAP trial, wherein somatostatin receptor-positive, advanced grade 1/2 gastroenteropancreatic NET patients were treated with [Lu]Lu-DOTATATE ± capecitabine.

Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial.

Lu-prostate-specific membrane antigen-617 (Lu-PSMA-617) has shown positive survival outcomes in metastatic castration-resistant prostate cancer. However, there are limited data in the hormone-sensitive setting. Here, in the CONSOLIDATE trial (Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer), we intended to evaluate the role of Lu-PSMA-617 as consolidation therapy for residual disease after chemohormonal treatment in patients with synchronous high-volume metastatic hormone-sensitive prostate cancer (mHSPC).

Safety and Efficacy of Peptide Receptor Radionuclide Therapy in Multiple Endocrine Neoplasia Syndrome: A Single-center Experience.

Purpose: Peptide receptor radionuclide therapy (PRRT) is recommended and approved in advanced neuroendocrine tumors (NETs). There is a lack of data on the utility of PRRT in multiple endocrine neoplasia (MEN) syndrome. This study explores the utility of PRRT in MEN syndrome patients with inoperable/metastatic NETs.

Exceptional Response to Rechallenge Peptide Receptor Radionuclide Therapy in Metastatic Carotid Body Tumor.

Carotid body tumor (CBT) is the most common head and neck paraganglioma with the very rare occurrence of distant metastases. The widespread distant metastases in head and neck paraganglioma have limited treatment options, with peptide receptor radionuclide therapy (PRRT) being an effective treatment in somatostatin receptor-expressing lesions. Here is a case of a 45-year-old woman with metastatic CBT who showed excellent response initially to 177Lu-DOTATATE PRRT, but presented later in wheel-chair bound condition with metastatic lesions and spinal cord compression at multiple levels, which again showed exceptional response to rechallenge PRRT.

Metastatic Mimicker in Thyroid Cancer with Thyroglobulin Elevation and an FDG-Avid Recurrent Aneurysmal Bone Cyst.

Many benign bone lesions mimic skeletal metastases from thyroid cancer on imaging and even may have high metabolic uptake on F-FDG PET/CT. It becomes crucial to distinguish these hypermetabolic lesions (benign vs. metastasis), especially in patients with thyroglobulin elevation and negative iodine scan.

PSMA-based Theranostics in Advanced Non-small Cell Lung Cancer​​​​​​: A Hit or a Miss?

Prostate-specific membrane antigen (PSMA) overexpression on prostate cancer cells finally led to the FDA approval of the therapeutic use of 177Lu-PSMA-617 in metastatic castrate-resistant prostate cancer. However, PSMA is also expressed in the neovasculature of other solid tumors, such as lung and renal cancer, making the theranostic potential of 177Lu-PSMA-617 worth exploring in this setting. Here is such a case of an 83-year-old man with advanced non-small cell lung cancer where the theranostic potential of 177Lu-PSMA-617 was explored using dosimetric analysis.

Utility of Cross-sectional and Correlative Imaging in Differentiated Thyroid Carcinoma with Unusual Presentation of Adrenal Metastases - Case Series and Review of Literature.

Differentiated thyroid carcinoma (DTC) metastasizing to the adrenal glands is very infrequent. We present three cases of DTC with adrenal metastasis in their follow-up, in which two were from follicular thyroid carcinoma and one from papillary thyroid carcinoma along with review of literature to emphasize the role of cross-sectional and correlative imaging in DTC with adrenal metastasis.

Mirrored Metastatic Neuroendocrine Tumor in a Mother-Daughter Duo With Mutations in the MEN1 Gene.

Multiple endocrine neoplasia (MEN) 1 syndrome may present with either of any or all neuroendocrine tumors (NETs), parathyroid and pituitary adenoma. There is a paucity of data on the intronic and exonic mutations in the MEN1 gene associated with the MEN1 syndrome. We present an interesting study of a mother-daughter duo of MEN1 who had a similar lesions distribution of metastatic NET and underwent genetic analysis to reveal a rare mutation in the MEN1 gene and both first-degree relatives presented with metastatic NET without any other syndromic manifestation of MEN1 syndrome.

Lu-DOTATATE Plus Capecitabine Versus Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial.

Lu-DOTATATE has emerged as a viable treatment strategy for advanced well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Few retrospective studies have shown concomitant Lu-DOTATATE with radiosensitizing low-dose capecitabine to be effective in advanced NETs. However, this has not been validated in prospective randomized-controlled trials.

Uncovering Hidden Metastases at Unusual Site: Emphasizing the Role of 177Lu-PSMA Posttherapy Scan in Detecting Rare Foot Metastasis in mCRPC.

Prostate cancer frequently metastasizes to bones; however, the detection of metastases can be challenging in rare locations. We present the case of a 76-year-old man with metastatic castration-resistant prostate cancer with lymph nodal and skeletal metastases who underwent 177Lu-prostate-specific membrane antigen (PSMA) therapy. Initial 18F-PSMA PET/CT scan acquired until the midthigh failed to identify metastases in the foot, but posttherapy 177Lu-PSMA scan revealed the presence of metastases in the navicular and cuboid bones of the right foot, which is a very rare finding.

Uncovering Hidden Metastases at Unusual Site: Emphasizing the Role of 177Lu-PSMA Posttherapy Scan in Detecting Rare Foot Metastasis in mCRPC.

Prostate cancer frequently metastasizes to bones; however, the detection of metastases can be challenging in rare locations. We present the case of a 76-year-old man with metastatic castration-resistant prostate cancer with lymph nodal and skeletal metastases who underwent 177Lu-prostate-specific membrane antigen (PSMA) therapy. Initial 18F-PSMA PET/CT scan acquired until the midthigh failed to identify metastases in the foot, but posttherapy 177Lu-PSMA scan revealed the presence of metastases in the navicular and cuboid bones of the right foot, which is a very rare finding.

Re-Rechallenge 177 Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer : A Step Further.

177 Lu-PSMA-617 radioligand therapy has been US Food and Drug Administration-approved safe and effective treatment modality for metastatic castration-resistant prostate cancer, usually administered in 4 to 6 cycles at 6 to 8 weeks apart. Many patients achieve partial response or stable disease with biochemical response after treatment. However, these effects are usually short-lived, and patients ultimately show disease progression after a median period of 6 to 9 months.

Localization in primary hyperparathyroidism.

Primary hyperparathyroidism is the main cause of hypercalcemia, resulting predominantly from parathyroid adenomas followed by hyperplasia. Diagnosis relies on clinical and biochemical parameters. Accurate pre-operative localization is mandatory for better surgical outcome.

Assessment of post-pyeloplasty renal drainage in antenatally detected hydronephrosis by Tc-L, L-Ethylenedicysteine renal scintigraphy: the importance of delayed imaging.

Objective: Diuretic renal scintigraphy is important in diagnosing pelvi-ureteric junction obstruction (PUJO) in antenatally detected hydronephrotic (ANH) kidneys. Early-phase dynamic renal scintigraphy has several pitfalls contributing to the false interpretation of obstructed drainage, especially after pyeloplasty. This study explores the utility of delayed imaging in Tc-L,L-Ethylenedicysteine (EC) diuretic renal scintigraphy to assess post-pyeloplasty renal drainage in ANH.

Diagnostic Accuracy of PSMA PET-Guided Prostate Biopsy in Prostate Cancer-A Systematic Review and Meta-analysis.

Purpose: Early diagnosis and treatment of prostate cancer (PC) are crucial for effective management and improved patient outcomes. Newer imaging modalities like prostate-specific membrane antigen PET have shown superior diagnostic performance in detecting PC and clinically significant PC (csPC). This systematic review and meta-analysis aims to synthesize evidence on the diagnostic performance of PSMA PET-guided prostate biopsy in detecting PC and csPC.

Incidentally Detected Gallbladder Carcinoma: Can F-18 FDG PET/CT Aid in Staging and Prognostication?

Purpose: Incidental gallbladder carcinoma (IGBC) is diagnosed in post-cholecystectomy specimens for benign indications, where the role of 2-fluro-2-deoxyglucose positron emission tomography/computed tomography(FDG-PET/CT) is not clearly defined. The present study aimed to assess the benefits of staging and prognosticating with FDG-PET/CT in IGBC.

Materials And Methods: A retrospective observational study from a tertiary-care center from January 2010 to July 2020 was performed.

Prostate-Specific Membrane Antigen-Avid Neurofibroma Mimicking Cutaneous Metastasis in Metastatic Castration-Resistant Prostate Cancer on 18 F-PSMA-1007 PET/CT.

The occurrence of cutaneous metastases in prostate cancer is exceedingly rare. Many benign lesions and nonprostatic cancers can express the prostate-specific membrane antigen (PSMA). They can potentially mimic metastasis of prostate cancer and lead to misinterpretation of PSMA PET/CT findings.

177 Lu-DOTATATE Salvage Therapy in Rapidly Progressing Neuroendocrine Tumor With Poor Performance Status.

Peptide receptor radionuclide therapy (PRRT) has shown to be effective and safe in metastatic gastroenteropancreatic and nongastroenteropancreatic neuroendocrine tumors. However, the selection criteria for PRRT are restricted to patients with good performance status (Eastern Cooperative Oncology Group score ≤2 or Karnofsky performance score ≥60). This denies many patients with adequate somatostatin receptor expression and biochemical profiles from the beneficial effects of PRRT on the quality of life, daily function, and overall survival.